Development of lipid-based drug delivery systems for poorly water-soluble drugs as viable oral dosage forms - Present status and future prospects

American Pharmaceutical Review

Volumn 11, Issue 2, 2008, Pages

  Serajuddin, Abu T M ^a   Li, Ping ^a   Haefele, Thomas F ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; LIPID;

DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG SOLUBILITY; LIPID SOLUBILITY; MICROEMULSION; SHORT SURVEY;

EID: 57349116207     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (40)

1. Vonderscher J, Meinzer A. 1994. Rationale for the development of Sandimmune Neoral. Transplant Proc 26: 2925-2927.
2. Meinzer A, Mueller E, Vonderscher J. 1995. Microemulsion - A suitable galenical approach for the absorption enhancement of low soluble compounds? BT Gattefosse 88:21-26.
3. Hauss DJ. 2006. Oral lipid-based drug delivery - A case of implementation failing to keep up with innovation? Am Pharm Rev, September/October issue (http://www.americanpharmaceuticalreview.com/, last accessed March 15, 2008).
4. Hauss DJ. 2007. Oral lipid-based formulations: Bridging the gap between knowledge and know-how. BT Gattefosse 100:9-11.
5. Reference Table: Description and Solubility, USP-NF 25 (official until April 25 2008), United States Pharmacopoeia, Rockville, MA.
6. Serajuddin, ATM. Personal communication.
7. Dannenfelser RM, He H, Joshi Y, Bateman S, Serajuddin ATM. 2004. Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. J Pharm Sci 93:1165-1175
8. Joshi HN, Tejwani RW, Varia SA, Serajuddin ATM. 2004. Bioavailability Enhancement of a Poorly Water-Soluble Drug by Solid Dispersion in Polyethylene Glycol-Polysorbate 80 Mixture. Int J Pharm 269:251-258.
9. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. Theoretical basis for a biopharmaceutical drug classification: correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
10. Serajuddin ATM. 2007. Salt formation to improve solubility, Adv Drug Del Rev 59:603-616.
11. Serajuddin ATM. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems and recent breakthroughs. J Pharm Sci 88:1058-1066.
12. Porter CJH, Pouton CW, Cuine JF, Charman WN. 2008. Enhancing intestinal drug solubilization using lipid-based delivery systems. Adv Drug Del Rev 60:673-691.
13. Perry CM, Noble S. 1998. Sequinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs 55:461-486.
14. Stuchlik M, Zak S. 2000. Lipid-based vehicle for oral drug delivery. Biomed Papers 145:17-26.
15. Khoo SM, Porter CJH, Charman WN. 2000. The formulation of halofantrine as either non-solubilising PEG6000 or solubilising lipid based solid dispersion: Physical stability and absolute bioavailability assessment. Int J Pharm 205:65-78.
16. Caliph SM, Charman WN, Porter CJH. 2000. Effect of short-. medium- and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J Pharm Sci 89:1073-1084.
17. Charman WN. 2000. Lipids, lipophilic drugs and oral drug delivery - some emerging concepts. J Pharm Sci 89:967-978.
18. Odeberg JM, Kaufmann P, Kroon KG, Hoegland P. 2003. Lipid drug delivery and rational formulation design for lipophilic drugs with low oral bioavailability, applied to cyclosporine. Eur J Pharm Sci 20:375-382.
19. Pouton CW. 2006. Formulation of poorly water-soluble drugs fro oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 29:278-287.
20. Porter CJH, Trevaskis NL, Charman WN 2007. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Disc 6:231-248.
21. O'Driscoll CM, Griffin BT. 2008. Biopharmaceutical challenges associated with drugs with low aqueous solubility - The potential impact of lipid-based formulations. Adv Drug Del Rev 60:617-624.
22. Strickley RG. 2007. Currently marketed oral lipid-based dosage forms: drug products and excipients. In Hauss D, editor. Lipid-based Formulations for Oral Drug Delivery: Enhancing Bioavailability of Poorly Water-Soluble Drugs, New York: Informa Healthcare p. 1-31.
23. Gibson L. 2007. Lipid-based excipients for oral drug delivery. In Hauss D, editor. Lipid-based Formulations for Oral Drug Delivery: Enhancing Bioavailability of Poorly Water-Soluble Drugs, New York: Informa Healthcare p. 33-61.
24. Shah NH, Carvalaj MT, Patel CI, Infeld MH, Malick AW. 1994. Self-emulsifying drug delivery systems (SEDDS) with polyglycolized glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm 106:14-23.
25. Constantinides PP. 1995. Lipid microemulsions for improving drug dissolution and oral absorption: Physical and biopharmaceutical aspects. Pharm Res 12:1561-1572.
26. Gursoy RN, Benita S. 2004. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 58:173-182.
27. Chen ML. 2008. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective. Adv Drug Del Rev 60:768-777.
28. Press release, Abbott to substitute Norvir capsules with liquid formulation. Abbott Laboratories, July 29, 1998.
29. Bauer J, Spanton S, Henry R, Quick J, Dziki W, Porter W, Morris J 2001. Ritonavir: An extraordinary example of conformational polymorphism. Pharm Res 18:859-866.
30. Pouton CW, Porter CJH 2008. Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. Adv Drug Del Rev 60:625-637.
31. Porter CJ, Kaukonen AM, Taillardat-Bertschinger A, Boyd BJ, O'Connor JM, Edwards GA, Charman WN, 2003. Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: Studies with halofantrine. J Pharm Sci 93:1110-1121.
32. Cuine JF, McEvoy CL, Charman WN, Pouton CW, Edwards GA, Benameur H, Porter CJH 2008. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations in dogs. J Pharm Sci 97:993-1010.
33. Taillardat A, Diederich A, Sutter B, Kalb O, Cuiné JF 2007. Use of in vitro dispersion and digestion tests to explain the in vivo performance of two lipid-based oral drug delivery systems in man. Am Pharm Rev, September/October, pp. 40-45 (http://www.americanpharmaceuticalreview.com/, last accessed March 15, 2008).
34. Rane SS, Anderson BD 2008. What determines drug solubility in lipid vehicles: Is it predictable? Adv Drug Del Rev 60:638-656.
35. Li P, Ghosh A, Wagner RF, Krill S, Joshi YM, Serajuddin 2005. Effect of combined use of non-ionic surfactants on formation of oil-in-water microemulsion. Int J Pharm 288:27-34.
36. Vasanthavada M, Serajuddin ATM. 2007. Lipid-based self-emulsifying solid dispersions. In Hauss D, editor. Lipid-based Formulations for Oral Drug Delivery: Enhancing Bioavailability of Poorly Water-Soluble Drugs, New York: Informa Healthcare p. 149-184.
37. Nazzal S, Smalyukh II, Lavrentovich OD, Khan MA 2002. Preparation and in vitro characterization of a eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS) of ubiquinone: mechanism and progress of emulsion formation. Int J Pharm 235:247-265.
38. Soliman MS, Khan MA 2005. Preparation and in vitro characterization of a semisolid dispersion of flurbiprofen with Gelucire 44/14 and Labrasol. Pharmazie 60:288-293.
39. Li P, Pudipeddi M, Hynes SR, Royce AE, Joshi YM, Serajuddin ATM. Development and Characterization of a Solid Microemulsion Preconcentrate System for Oral Delivery of Poorly Water Soluble Drugs. Presented at Controlled Release Society Annual Meeting, Long Beach, CA, June 2007.
40. Li P, Pudipeddi M, Hynes SR, Haefele T. Royce AE, Joshi YM, Serajuddin ATM. Development of clinical dosage forms for a poorly water-soluble drug II: Development and characterization of a solid microemulsion preconcentrate system for oral delivery of poorly water-soluble drugs. J Pharm Sci (submitted).